PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-426.32
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1668.23
Negative FCF while AVXL shows P/FCF of 1415.04. Joel Greenblatt would examine cash flow improvement potential.
-1668.23
Negative operating cash flow while AVXL shows P/OCF of 1415.04. Joel Greenblatt would examine operational improvement potential.
No Data
No Data available this quarter, please select a different quarter.
-0.06%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-0.06%
Negative FCF while AVXL shows yield of 0.07%. Joel Greenblatt would examine cash flow improvement potential.